Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer

• Sponsor: Seagen Inc. (Industry)
• Overall Status: No longer available
• CT.gov ID: NCT03424473
• Collaborator: (none)

Study Details

Study Description

Brief Summary

Physicians interested in requesting a single patient IND should contact Seattle Genetics' Medical Information ([e-mail]).

Condition or Disease	Intervention/Treatment	Phase
	Drug: Tucatinib

Study Design

• Study Type: Expanded Access

Outcome Measures

Primary Outcome Measures

Eligibility Criteria

Criteria

• Ages Eligible for Study: N/A and Older
• Sexes Eligible for Study: All

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

• Seagen Inc.

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Seagen Inc.
• ClinicalTrials.gov Identifier: NCT03424473
• Other Study ID Numbers: ONT-380-014
• First Posted: Feb 7, 2018
• Last Update Posted: Feb 25, 2020
• Last Verified: Feb 1, 2020

• Keywords provided by Seagen Inc.: tucatinib; Breast Cancer; ARRY-380; ONT-380; HER2 Positive Breast Carcinoma; HER2 Positive Locally Advanced Breast Cancer; HER-2 Positive Breast Cancer; HER-2 Positive Locally Advanced Breast Cancer; Recurrent Breast Carcinoma; Stage IV Breast Cancer; Metastatic Breast Cancer; Breast Carcinoma; Metastatic Malignant Neoplasm in the Brain; Brain Metastases in Breast Cancer; Breast Neoplasms; Neoplasms by Site; Neoplasms; Breast Diseases
• Additional relevant MeSH terms: Tucatinib

Study Results

No Results Posted as of Feb 25, 2020